In the past week, UBX stock has gone down by -11.67%, with a monthly decline of -37.28% and a quarterly surge of 10.37%. The volatility ratio for the week is 14.14%, and the volatility levels for the last 30 days are 10.48% for Unity Biotechnology Inc The simple moving average for the past 20 days is -29.45% for UBX’s stock, with a -28.75% simple moving average for the past 200 days.
Is It Worth Investing in Unity Biotechnology Inc (NASDAQ: UBX) Right Now?
Additionally, the 36-month beta value for UBX is 1.31. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for UBX is 15.38M and currently, short sellers hold a 4.16% ratio of that float. The average trading volume of UBX on April 03, 2025 was 283.96K shares.
UBX) stock’s latest price update
Unity Biotechnology Inc (NASDAQ: UBX)’s stock price has gone rise by 10.41 in comparison to its previous close of 0.96, however, the company has experienced a -11.67% decrease in its stock price over the last five trading days. zacks.com reported 2025-03-25 that UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
Analysts’ Opinion of UBX
Many brokerage firms have already submitted their reports for UBX stocks, with Rodman & Renshaw repeating the rating for UBX by listing it as a “Buy.” The predicted price for UBX in the upcoming period, according to Rodman & Renshaw is $8 based on the research report published on August 22, 2024 of the previous year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see UBX reach a price target of $4, previously predicting the price at $2. The rating they have provided for UBX stocks is “Outperform” according to the report published on November 16th, 2023.
UBX Trading at -41.70% from the 50-Day Moving Average
After a stumble in the market that brought UBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.81% of loss for the given period.
Volatility was left at 10.48%, however, over the last 30 days, the volatility rate increased by 14.14%, as shares sank -37.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.78% lower at present.
During the last 5 trading sessions, UBX fell by -11.67%, which changed the moving average for the period of 200-days by -29.80% in comparison to the 20-day moving average, which settled at $1.5025. In addition, Unity Biotechnology Inc saw 8.56% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at UBX starting from Nguyen Alexander Hieu, who sale 1,954 shares at the price of $1.16 back on Mar 27 ’25. After this action, Nguyen Alexander Hieu now owns 22,605 shares of Unity Biotechnology Inc, valued at $2,267 using the latest closing price.
Sullivan Lynne Marie, the CFO & Head of Corp. Dev. of Unity Biotechnology Inc, sale 153 shares at $2.23 during a trade that took place back on Feb 04 ’25, which means that Sullivan Lynne Marie is holding 55,772 shares at $341 based on the most recent closing price.
Stock Fundamentals for UBX
The total capital return value is set at -1.1. Equity return is now at value -148.97, with -48.99 for asset returns.
Based on Unity Biotechnology Inc (UBX), the company’s capital structure generated 0.78 points at debt to capital in total, while cash flow to debt ratio is standing at -0.89.
Currently, EBITDA for the company is -31.17 million with net debt to EBITDA at -0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.62.
Conclusion
In conclusion, Unity Biotechnology Inc (UBX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
